Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.39 |
| ▸ | ITGAV | P06756 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046224 | 1.00 | ITGB3 (0.39) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL8327726 | 1.00 | ITGB3 (0.39) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL1378559 | 1.00 | ITGB3 (0.39) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL14143519 | 0.93 | ITGB3 (0.36) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL4682248 | 0.93 | ITGB3 (0.36) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL4681624 | 0.93 | ITGB3 (0.36) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL7163504 | 0.91 | ACE (0.41) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL7163716 | 0.91 | ACE (0.41) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL7165621 | 0.91 | ITGB3 (0.39) | ITGB3ITGAVHSD17B10TSHRMEN1 | |
| SCHEMBL7163786 | 0.90 | ITGB3 (0.36) | ITGB3ITGAVHSD17B10TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285792-A1 | Compositions and methods for treatment of neovascular diseases | THE SCRIPPS RESEARCH INSTITUTE | 2009-11-19 | — | — | US | disclosed |
| US-7528106-B2 | Compositions and methods for treatment of neovascular diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1594853-B1 | METHOD FOR THE PRODUCTION OF BICYCLIC AROMATIC AMINO ACIDS AND INTERMEDIATE PRODUCTS THEREOF | MERCK PATENT GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-7371854-B2 | Method for the production of bicyclic aromatic amino acids and intermediate products thereof | MERCK PATENT GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-7371854-B2 | Method for the production of bicyclic aromatic amino acids and intermediate products thereof | MERCK PATENT GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20060142568-A1 | Method for the production of bicyclic aromatic amino acids and intermediate products thereof | MEREK PATENT GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | MERCK PATENT GESELLSCHAFT (DE) | 2004-10-07 | — | — | US | disclosed |
| EP-1411926-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-6559144-B2 | Integrin inhibitors used to treat circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, pathological processes maintained or propagated by angiogenesis and tumor therapy | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-05-06 | — | — | US | disclosed |
| WO-2003013511-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
| EP-0964856-B1 | BICYCLIC AMINO ACIDS | MERCK PATENT GMBH (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20010021709-A1 | Bicyclic amino acids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKT PATENTS (DE) | 2001-09-13 | — | — | US | disclosed |
| EP-0964856-A1 | BICYCLIC AMINO ACIDS | MERCK PATENT GmbH (DE) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998035949-A1 | BICYCLIC AMINO ACIDS | MERCK PATENT GMBH (DE) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | ITGB3 5/4885ITGAV 3/4885HSD17B10 4782/4885 |
| US-20010021709-A1 | Bicyclic amino acids | ITGA1, ITGB1, ITGB2 | ITGB3 5/4885ITGAV 15/4885HSD17B10 4576/4885 |
| US-20060142568-A1 | Method for the production of bicyclic aromatic amino acids and intermediate products thereof | ITGA1, ITGB1, ITGA2 | ITGB3 8/4885ITGAV 16/4885HSD17B10 4570/4885 |
| US-20090285792-A1 | Compositions and methods for treatment of neovascular diseases | TEK, KDR, WARS1 | ITGB3 24/4885ITGAV 16/4885HSD17B10 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.